Apexigen Announces First Patient Dosed in Phase 3 Pivotal Trial for BD0801, an Anti-VEGF Monoclonal Antibody, in Combination Therapy for Ovarian Cancer

NEXT STORY
Dermal Fillers Market Size to Outstrip $9,421.33Mn by 2028 Growth Projections at 11.5% CAGR During 2021 to 2028 COVID Impact and Global Analysis by TheInsightPartners.com
PREV STORY
Statera Biopharma, Inc. to Participate in the A.G.P. Biotech and Specialty Pharma Conference
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

pSivida’s Medidur for Posterior Uveitis Granted Orphan Drug Designation in Europe

WATERTOWN, Mass., May 02, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA),  a leader ...

author_avatar
NASDAQ Market News

Corbus Pharmaceuticals Announces Presentation of Six Abstracts at EULAR 2019 Annual Meeting

author_avatar
NASDAQ Market News

Zai Lab Announces First Patient Treated in Greater China in PANOVA-3 Phase 3 Pivotal Trial of Tumor Treating Fields in Pancreatic Cancer

author_avatar
NASDAQ Market News